Amedisys Financial Statements (AMED)
|
|
Report date
|
|
|
24.02.2022 |
31.12.2022 |
16.02.2023 |
22.02.2024 |
26.04.2024 |
|
07.11.2024 |
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
2 214 |
2 223 |
2 223 |
2 236 |
2 236 |
|
2 341 |
Operating Income, bln rub |
|
|
251.9 |
180.8 |
180.8 |
193.1 |
156.4 |
|
180.7 |
EBITDA, bln rub |
? |
|
320.7 |
183.5 |
207.4 |
216.9 |
216.9 |
|
185.5 |
Net profit, bln rub |
? |
|
209.1 |
118.6 |
118.6 |
-9.75 |
-9.75 |
|
179.0 |
|
OCF, bln rub |
? |
|
188.9 |
133.3 |
133.3 |
137.2 |
137.2 |
|
270.5 |
CAPEX, bln rub |
? |
|
6.72 |
6.17 |
7.22 |
12.7 |
12.7 |
|
6.45 |
FCF, bln rub |
? |
|
182.2 |
127.1 |
126.1 |
124.5 |
124.5 |
|
264.1 |
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
25.7 |
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
14.4% |
|
OPEX, bln rub |
|
|
728.8 |
2 042 |
779.0 |
264.0 |
834.5 |
|
1 700 |
Cost of production, bln rub |
|
|
1 233 |
0.000 |
1 260 |
1 779 |
1 779 |
|
865.4 |
R&D, bln rub |
|
|
0.000 |
0.000 |
3.00 |
3.80 |
3.80 |
|
3.80 |
Interest expenses, bln rub |
|
|
9.53 |
22.2 |
22.2 |
31.3 |
31.3 |
|
31.8 |
|
Assets, bln rub |
|
|
1 857 |
1 976 |
1 976 |
2 060 |
2 060 |
|
2 139 |
Net Assets, bln rub |
? |
|
931.4 |
1 052 |
1 052 |
1 067 |
1 067 |
|
1 148 |
Debt, bln rub |
|
|
545.6 |
542.7 |
537.9 |
487.2 |
487.2 |
|
468.6 |
Cash, bln rub |
|
|
42.7 |
40.5 |
40.5 |
145.9 |
126.5 |
|
245.5 |
Net debt, bln rub |
|
|
502.9 |
502.2 |
497.4 |
341.4 |
360.8 |
|
223.1 |
|
Ordinary share price, rub |
|
|
161.9 |
83.5 |
83.5 |
95.1 |
95.1 |
|
91.4 |
Number of ordinary shares, mln |
|
|
32.6 |
32.6 |
32.5 |
32.6 |
32.5 |
|
32.7 |
|
Market cap, bln rub |
|
|
5 284 |
2 720 |
2 716 |
3 099 |
3 088 |
|
2 993 |
EV, bln rub |
? |
|
5 787 |
3 222 |
3 214 |
3 440 |
3 449 |
|
3 216 |
Book value, bln rub |
|
|
-376 |
-337 |
-337 |
-281 |
-281 |
|
-197 |
|
EPS, rub |
? |
|
6.40 |
3.64 |
3.65 |
-0.30 |
-0.30 |
|
5.47 |
FCF/share, rub |
|
|
5.58 |
3.90 |
3.88 |
3.82 |
3.83 |
|
8.07 |
BV/share, rub |
|
|
-11.5 |
-10.4 |
-10.4 |
-8.61 |
-8.64 |
|
-6.00 |
|
EBITDA margin, % |
? |
|
14.5% |
8.25% |
9.33% |
9.70% |
9.70% |
|
7.92% |
Net margin, % |
? |
|
9.44% |
5.34% |
5.34% |
-0.44% |
-0.44% |
|
7.65% |
FCF yield, % |
? |
|
3.45% |
4.67% |
4.64% |
4.02% |
4.03% |
|
8.82% |
ROE, % |
? |
|
22.4% |
11.3% |
11.3% |
-0.91% |
-0.91% |
|
15.6% |
ROA, % |
? |
|
11.3% |
6.00% |
6.00% |
-0.47% |
-0.47% |
|
8.37% |
|
P/E |
? |
|
25.3 |
22.9 |
22.9 |
-317.9 |
-316.9 |
|
16.7 |
P/FCF |
|
|
29.0 |
21.4 |
21.5 |
24.9 |
24.8 |
|
11.3 |
P/S |
? |
|
2.39 |
1.22 |
1.22 |
1.39 |
1.38 |
|
1.28 |
P/BV |
? |
|
-14.1 |
-8.07 |
-8.06 |
-11.0 |
-11.0 |
|
-15.2 |
EV/EBITDA |
? |
|
18.0 |
17.6 |
15.5 |
15.9 |
15.9 |
|
17.3 |
Debt/EBITDA |
|
|
1.57 |
2.74 |
2.40 |
1.57 |
1.66 |
|
1.20 |
|
R&D/CAPEX, % |
|
|
0.00% |
0.00% |
41.6% |
29.9% |
29.9% |
|
59.0% |
|
CAPEX/Revenue, % |
|
|
0.30% |
0.28% |
0.32% |
0.57% |
0.57% |
|
0.28% |
|
Amedisys shareholders |